When a Philadelphia jury awarded three plaintiffs’ hormone replacement therapy cases against Pfizer last week at a combined total of $72.6 million in compensatory damages, plaintiffs attorneys said the verdict was all the more significant because it was rendered after the first phase of a reverse-bifurcated trial.

The parties confirmed that those cases settled for undisclosed amounts on the eve of the second phase of trial, which was originally scheduled to open Dec. 9.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]